Skip to main content

Advertisement

Table 2 Incidence of local and systemic reactions reported for the two vaccine groups

From: Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

   Sub/MF59™ %(n) Subunit %(n)
Local reaction Rash 0.0(0) 0.5(1)
  Erythema 1.5(6) 1.5(3)
  Induration 0.5(2) 2.5(5)*
  Swelling 2.8(11) 1.0(2)
  Pain 10.2(40)** 3.0(6)
  Pruritus 1.3(5) 3.0(6)
Systemic reaction Headache 3.6(14) 2.5(5)
  Fever 15.9(62)** 7.6(15)
  Tiredness 3.3(13) 1.0(2)
  Diarrhoea 0.8(3) 2.0(4)
  Vomiting 1.0(4) 1.0(2)
  Myalgia 1.8(7) 0.5(1)
  Cough 2.0(8) 2.0(4)
  Angina 1.5(6) 1.0(2)
  Watery nasal discharge 1.0(4) 1.0(2)
  Skin disease (e.g. eczema) 0.0(0) 1.0(2)
  Irritability 0.0(0) 0.5(1)
  1. *P < 0.05 versus the Sub/MF59™ vaccine group; **P ≤ 0.005 versus the Subunit vaccine group
  2. Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine